Feds expand probe into electric unicycles and sneaky components
Published Date: 9/18/2026
Notice
Summary
The U.S. International Trade Commission is moving forward with a case about gyro-stabilized electric unicycles, adding a new company, LeaperKim Coyote, to the investigation. This affects companies importing or selling these unicycles in the U.S., with potential impacts on sales and patents. The case started in March 2026 and is now expanding, signaling serious attention to patent rights and market control.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
LeaperKim Coyote Added as Respondent
On September 15, 2026 the U.S. International Trade Commission voted not to review an ALJ order and added Guangzhou Coyote Intelligent Equipment Co., Ltd. d/b/a LeaperKim ("LeaperKim Coyote") as a respondent in Investigation No. 337-TA-1488. The ALJ issued the initial determination granting the amendment on August 18, 2026 after a motion filed August 7, 2026.
Section 337 Patent Infringement Allegations
The investigation, instituted March 5, 2026, alleges violations of section 337 (19 U.S.C. 1337) for importation into the United States, sale for importation, and sale within the United States of certain gyro-stabilized electric unicycles and components by reason of infringement of U.S. Patent No. 8,807,250 and U.S. Patent No. D729,698. The complaint also alleges that a U.S. industry exists or is in the process of being established.
Inmotion Terminated After Settlement
Respondent Inmotion Technologies Co., Ltd. d/b/a Inmotion was terminated from this investigation based on a settlement agreement (Order No. 11, May 21, 2026), as noted in the Commission notice dated June 18, 2026. That termination removes Inmotion from Investigation No. 337-TA-1488.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20752, Certain Hydrodermabrasion Systems and Components Thereof; Notice of Vacatur of the Commission's Final Determination and Mootness of the Investigation by the Federal Circuit Due to Patent Expiration
The U.S. International Trade Commission's investigation into certain hydrodermabrasion systems has been canceled because the key patent expired. This affects companies like HydraFacial and Cartessa, ending any legal battles over these products. The case officially closed in March 2026, so no money penalties or import bans will happen now.
2026-20672, Certain Mobile Electronic Devices and Components Thereof; Institution of Investigation
The U.S. International Trade Commission is launching an investigation into certain mobile electronic devices and their parts because trinamiX Sensing LLC and trinamiX GmbH say some products are using their patented technology without permission. This could lead to orders stopping imports and sales of these devices in the U.S., affecting companies involved and possibly shaking up the market soon. The investigation started after complaints filed in September 2026 and could impact money and product availability.
2026-20609, Oleoresin Paprika From India; Determinations
The U.S. International Trade Commission found that imports of oleoresin paprika from India are hurting American businesses because they’re being sold at unfairly low prices and getting government subsidies. This means U.S. companies like Rezolex, Ltd. Co. get some protection through trade rules starting now. Importers and sellers of this spice should expect changes that could affect prices and supply soon.
2026-20614, Forged Steel Fittings From India and South Korea; Cancellation of Hearing for Antidumping and Countervailing Duty Reviews
The U.S. International Trade Commission has canceled the public hearing for the review of antidumping and countervailing duties on forged steel fittings from India and South Korea. This change affects companies like Bonney Forge and related unions, who will now answer questions without a formal hearing. The cancellation speeds up the process, with no immediate money changes but keeps the review on track.
2026-20673, Seamless Carbon and Alloy Steel Standard, Line, and Pressure Pipe From Czechia, Russia, South Korea, and Ukraine; Scheduling of Full Five-Year Reviews
The U.S. International Trade Commission is kicking off a full review to decide if special duties on seamless steel pipes from Czechia, Russia, South Korea, and Ukraine should stay or go. This review could impact import costs and the steel market, with decisions expected soon after a possible 90-day extension. Steel makers, importers, and users should keep an eye on this as it could affect prices and supply.
2026-20349, Railway Tank Cars and Parts Thereof From Mexico; Institution of Antidumping and Countervailing Duty Investigations and Scheduling of Preliminary Phase Investigations
The U.S. is launching investigations to see if cheap railway tank cars and parts from Mexico are hurting American businesses. If these imports are found to be unfairly priced or subsidized, extra duties might be added to protect U.S. makers. The first big decision is due by November 16, 2026, so things are moving fast!
Previous / Next Documents
Previous: 2026-19164, Environmental Impact Statements; Notice of Availability
The EPA just shared new Environmental Impact Statements (EIS) for projects like dam upgrades and transit expansions that affect communities in California, Washington, and Utah. These reports help everyone understand how projects might impact the environment, and you’ve got until early November or October to share your thoughts. No big money changes announced, but these updates keep important projects moving safely and smartly.
Next: 2026-19166, Biosimilar User Fee Act III Future Needs in the Development of Interchangeable Products Post-Workshop; Draft Strategy Document
The FDA just shared a draft plan to help make interchangeable biosimilar drugs easier to develop and approve. This affects drug makers and patients who want more affordable medicine options. The FDA wants your feedback by November 17, 2026, before finalizing the plan, which supports innovation and smoother drug approvals through 2027.